医学
药品
加药
临床试验
药品审批
重症监护医学
肿瘤科
内科学
医学物理学
药理学
作者
Mirat Shah,Atiqur Rahman,Marc R. Theoret,Richard Pazdur
摘要
Doses and schedules of oncology drugs are sometimes inadequately characterized before registration trials. The “more is better” paradigm is still used for dose selection, despite the recognition that targeted therapies require alternative approaches to dose optimization.
科研通智能强力驱动
Strongly Powered by AbleSci AI